Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.64 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.62 |
| ▸ | AXL | P30530 | 8/20 | 0.61 |
| ▸ | MERTK | Q12866 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161171 | 0.87 | MET (0.66) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL2425285 | 0.86 | MET (0.60) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL12561530 | 0.86 | MET (0.62) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL14411985 | 0.86 | MET (0.61) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL13212979 | 0.81 | AXL (0.60) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL19377723 | 0.81 | MET (0.56) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL29626156 | 0.81 | MET (0.56) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL18256977 | 0.81 | MET (0.57) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL13368441 | 0.80 | POLB (0.55) | METRIPK3RIPK2AXLMERTK | |
| SCHEMBL12560888 | 0.79 | AXL (0.63) | METAXLMERTKTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2009033084-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MET 357/4885RIPK3 870/4885RIPK2 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.